Merckle GmbH
🇩🇪Germany
Clinical Trials
26
Active:23
Completed:3
Trial Phases
1 Phases
Phase 1:25
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 1
25 (100.0%)Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 49
- Registration Number
- NCT02592031
PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT02306915
- Locations
- 🇬🇧
Teva Investigational Site 34193, London, United Kingdom
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Phase 1
Completed
- Conditions
- Ewing Family of Tumors, Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 21
- Registration Number
- NCT01585649
- Locations
- 🇧🇬
Teva Investigational Site 0103, Plovdiv, Bulgaria
🇧🇬Teva Investigational Site 0101, Sofia, Bulgaria
🇧🇬Teva Investigational Site 0102, Varna, Bulgaria
News
No news found